Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q3 2022 · 10-Q
Revenue$10.41B$10.41B−4.7% vs Q3 2021 Net Income$1.44B$1.44B−31.7% vs Q3 2021 EPS Diluted$0.81$0.81−30.8% vs Q3 2021 Operating Income$1,770,000,000−30.5% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$2,313,000,000+3.3% Margins · derivedOperating margin17.0%−6.3 pt vs Q3 2021
Net margin13.8%−5.4 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 1, 2022 · 32 d after period end